TScan Therapeutics (TCRX) Stock Price, News & Analysis

Company Overview

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors. TScan has established strategic collaborations with major pharmaceutical partners to advance its lead candidates through clinical development. These partnerships enable the company to combine its TCR discovery capabilities with the resources and expertise of established drug developers, while retaining the ability to progress additional assets independently.

Founded in 2018 and headquartered in Cambridge, Massachusetts, TScan Therapeutics went public in late 2021. Under the leadership of Chief Executive Officer Kenneth Song, the company employs a multidisciplinary team of immunologists, molecular biologists and data scientists. While its core operations are based in the United States, TScan’s research partnerships and clinical trial activities extend globally, reflecting its ambition to deliver novel T-cell therapies to patients around the world.

Key Stats

• Today's Range: $1.03 to $1.10
• 50-Day Range: $0.84 to $1.26
• 52-Week Range: $0.83 to $2.57
• Volume: 968,742 shs
• Average Volume: 829,207 shs
• Market Capitalization: $71.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Hold

TScan Therapeutics Stock Analysis - MarketRank™

TScan Therapeutics scored higher than 86% of companies evaluated by MarketBeat, and ranked 71st out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

TScan Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

TScan Therapeutics has a consensus price target of $6.00, representing about 450.5% upside from its current price of $1.09.

Amount of Analyst Coverage

TScan Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for TScan Therapeutics are expected to grow in the coming year, from ($1.11) to ($0.99) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of TScan Therapeutics is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of TScan Therapeutics is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

TScan Therapeutics has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.16% of the float of TScan Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

TScan Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in TScan Therapeutics has recently decreased by 7.12%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TScan Therapeutics does not currently pay a dividend.

Dividend Growth

TScan Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: N/A

News Sentiment

TScan Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for TScan Therapeutics this week, compared to 2 articles on an average week.

Search Interest

12 people have searched for TCRX on MarketBeat in the last 30 days. This is an increase of 1,100% compared to the previous 30 days.

MarketBeat Follows

4 people have added TScan Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, TScan Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.25% of the stock of TScan Therapeutics is held by insiders.

Percentage Held by Institutions

82.83% of the stock of TScan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 7/12/2026
• Next Earnings (Estimated): 8/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TCRX
• CIK: 1783328
• Web: www.tscan.com
• Phone: 857-399-9500
• Fax: N/A
• Employees: 100
• Year Founded: 2018

Price Target and Rating

• Average Price Target for TScan Therapeutics: $6.00
• High Price Target: $7.00
• Low Price Target: $5.00
• Potential Upside/Downside: +450.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.96)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$129.77 million
• Net Margins: -1,360.61%
• Pretax Margin: -1,360.61%
• Return on Equity: -91.94%
• Return on Assets: -50.15%

Debt

• Debt-to-Equity Ratio: 0.34
• Current Ratio: 6.65
• Quick Ratio: 6.65

Sales & Book Value

• Annual Sales: $10.32 million
• Price / Sales: 6.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.16 per share
• Price / Book: 0.50

Miscellaneous

• Outstanding Shares: 65,350,000
• Free Float: 61,267,000
• Market Cap: $71.23 million
• Optionable: Not Optionable
• Beta: 1.04